Figure 3
Arthritic ASIC3−/− mice show reduced mechanical hyperalgesia in the late phase. (A) Arthritis scores in ASIC3+/+, ASIC3+/− and ASIC3−/− mice. *P < 0.05, **P < 0.01, ***p < 0.001, compared with ASIC3+/+ mice by two-way ANOVA. (B) Joint swelling in 0, 4, 8, 12 weeks in ASIC3−/− mice. (C,D) PWT measured at weekly intervals after the first CFA injection. Data are mean ± SEM of total tested mice (n = 6 for ASIC3+/+, n = 8 for ASIC3+/−, n = 8 for ASIC3−/− group). *p < 0.05, **P < 0.01, ***p < 0.001, ASIC3−/− vs ASIC3+/+ by two-way ANOVA. (E,F) qRT-PCR analysis of TDAG8 or TRPV1 gene expression in ipsilateral DRG at 12 weeks of ASIC3+/+ or ASIC3−/− mice, or at 0 weeks of ASIC3+/+ mice (ctrl). ***p < 0.001, ASIC3-/- vs ASIC3+/+; ###p < 0.001, ASIC3+/+ vs ctrl by one-way ANOVA. (G) Samples of joints at 4, 8, 12 weeks stained with hematoxylin and eosin are shown in (a-l). Data are mean ± SEM severity score for synovial inflammation (H), bone erosion (I), and cartilage damage (J). *p < 0.05, **P < 0.01, comparing ASIC3−/− vs wild type (WT) by nonparametric Mann-Whitney U test.
